NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 206)
Posted On: 03/08/2022 3:34:13 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has been granted an Australian patent titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The patent expands Lexaria’s world patent portfolio to 24. According to the announcement, the patent expands the company’s international intellectual property rights to apply its proprietary DehydraTECH(TM) enhancement technology to most oral forms of nicotine delivery, which would include pills, tablets, lozenges, capsules, pouches, gums and sprays. In addition to covering different forms of delivery, the patent also includes an array of nicotine forms, such as free base nicotine, nicotine salts, polymer resins of nicotine and other forms of nicotine complexes. This is the first patent awarded from LEXX’s eighth patent family; a first patent in a new patent family often leads to additional patents granted in that same family. Lexaria noted that it has pending patent applications in other countries, including the United States. The company also noted nine patent claims have been granted the government of Australia.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has been granted an Australian patent titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The patent expands Lexaria’s world patent portfolio to 24. According to the announcement, the patent expands the company’s international intellectual property rights to apply its proprietary DehydraTECH(TM) enhancement technology to most oral forms of nicotine delivery, which would include pills, tablets, lozenges, capsules, pouches, gums and sprays. In addition to covering different forms of delivery, the patent also includes an array of nicotine forms, such as free base nicotine, nicotine salts, polymer resins of nicotine and other forms of nicotine complexes. This is the first patent awarded from LEXX’s eighth patent family; a first patent in a new patent family often leads to additional patents granted in that same family. Lexaria noted that it has pending patent applications in other countries, including the United States. The company also noted nine patent claims have been granted the government of Australia.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼